Business ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs GLP-1 Drugs Acquisitions Eli Lilly Oncology Novo Nordisk Weight Loss Medications Alzheimer's Disease Anti-Obesity Drugs FDA Regulations Obesity Treatments Tirzepatide Monoclonal Antibodies Sales Performance Cancer Treatments Cancer Treatment Stelara Biosimilar Drugs Weight Loss Treatments COPD Treatment Obesity Drugs Biologic Medicines Partnerships Weight-loss Drugs Merck AstraZeneca Anti-Cancer Drugs Semaglutide Rare Diseases Sarepta Therapeutics Vertex Pharmaceuticals Dupixent Market Readiness Lead Optimization Upadacitinib Wockhardt Rinvoq Regulatory Approval Precision Medicine Innovative Drugs Eli Lilly Products AbbVie Inc. Silevertinib Efficacy Studies GSK plc Rheumatoid Arthritis Rigel Pharmaceuticals Breyanzi Novo Nordisk A/S Clinical-stage Companies Regulatory Affairs Immuno-Oncology New Drug Application Antibody-Drug Conjugates Market Opportunities Orforglipron Weight Management Vaccines Eylea Briumvi Radical Innovation Incremental Innovation Market Strategies Diabetes Treatments Casgevy Efzofitimod Patent Expiration Influenza Treatments LUMRYZ™ Approval Metsera Flu Antivirals Immunology Market Growth Corticosteroids Blockbuster Drugs Market Performance Market Expansion Wet Age-Related Macular Degeneration Investment Plans FDA Approval Vyndaqel Family of Drugs Pfizer AbbVie Concussion Treatment Vaccine Rollout Pfizer Inc RELYVRIO Neuroplastogenic Therapeutics Springworks Therapeutics Multiple Sclerosis Treatments Market Competition Autoimmune Disease Treatments Novartis Weight Loss Treatment Oral Weight Loss Pill Weight-Loss Drugs

Bristol Myers Strikes Up to $850 Million Janux Deal for Tumor-Activated T-Cell Engager

The deal centers on Janux’s masked technology intended to trigger T-cell activity only inside tumors.

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

TG Therapeutics Lifts 2026 Outlook After Strong Briumvi Year, Shares Jump

Eli Lilly Prepares €15 Billion Abivax Offer, Eyes Next Wave of Weight-Loss Drugs

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength

HSBC Upgrades AbbVie to Buy, Lifts Target to $265 as Skyrizi and Rinvoq Drive Growth

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

Race for Lead Plaintiff in aTyr Securities Case Nears Dec. 8 Deadline After Phase 3 Trial Failure

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

MoonLake Investor Lawsuits Press Toward Lead-Plaintiff Cutoff as December 15 Deadline Nears

Biogen, Dayra Launch $50 Million Pact to Develop Oral Macrocyclic Peptides for Immunology

Eli Lilly Briefly Hits $1 Trillion, First Drugmaker to Reach the Milestone

MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Casgevy Launch Stumbles, Yet Analysts Eye Upside for CRISPR Therapeutics